This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Express Scripts (ESRX) Earnings Top in Q1, FY17 View Up
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted first-quarter 2017 adjusted earnings per share of $1.33, beating the Zacks Consensus Estimate by a penny.
C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.87 in the first quarter of 2017, exceeding the Zacks Consensus Estimate of $2.65.
Baxter Launches Drug Library Guide for Smart Infusion System
by Zacks Equity Research
Baxter International Inc. (BAX) recently introduced an infusion system drug library guide to help clinicians identify potential errors in the infusion process during intravenous treatment.
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown
by Zacks Equity Research
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.
Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View
by Zacks Equity Research
Quest Diagnostics' (DGX) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate.
Inogen, Avis Budget Group, Qualcomm, American Express and CSX highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Inogen, Avis Budget Group, Qualcomm, American Express and CSX highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Inogen (INGN)
by David Bartosiak
Medical devices offer a less volatile area of the biotech market
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.
Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device
by Zacks Equity Research
Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical Inc.(ISRG) posted adjusted earnings of $4.67 per share in the first quarter of 2017, crushing the Zacks Consensus Estimate of $3.97 on stellar revenue growth.
GNC Holdings (GNC) Q1 Earnings & Revenues Top, Decline Y/Y
by Zacks Equity Research
GNC Holdings Inc. (GNC) reported first-quarter 2017 adjusted earnings per share (EPS) of 37 cents, reflecting a massive 46.4% year-over-year deterioration.
Abbott Laboratories Agrees to Acquire Alere at Lower Price
by Zacks Equity Research
Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share upon the completion of the transaction.
Mazor (MZOR) Gets FDA Clearance For Mazor X Align Software
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it has received the FDA clearance for its Mazor X Align software.
Aetna (AET) Hurt by Exchange Business, High Medical Costs
by Zacks Equity Research
Shares of health insurer Aetna Inc. (AET) underperformed over the past one year.
Boston Scientific's Emerging Markets Grow Amid Currency Woes
by Zacks Equity Research
On Apr 11 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Quality Systems (QSII) to Acquire Entrada for $34 Million
by Zacks Equity Research
Quality Systems, Inc. announced that it has entered into a deal to acquire Entrada, Inc. for $34 million.
Align (ALGN) Upgraded to Buy on Invisalign System Prospects
by Zacks Equity Research
On Apr 11, leading provider of dental and oral care solutions, Align Technology Inc. (ALGN) was raised to a Zacks Rank #2 (Buy).
Trump Amending AHCA: Is the Medical Device Space Anxious?
by Zacks Equity Research
In a bid to save its face, the Trump administration is attempting to keep the American Health Care Act viable by proposing a new amendment to the bill.
Should You Retain Universal Health (UHS) Stock in Portfolio?
by Zacks Equity Research
Universal Health Services, Inc. (UHS) stock has gained 9% in last three months, outperforming the Zacks Hospitals industry's increase of 7.6%.
Haemonetics' Plasma Group Strong, Blood Center Group a Drag
by Zacks Equity Research
On Apr 11, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE), a leading provider of blood management solutions.
Accuray TomoTherapy System Starts Cancer Treatment in Africa
by Zacks Equity Research
Accuray Inc. (ARAY) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company's flagship TomoTherapy system.
athenahealth (ATHN) Allies with CoverMyMeds for Faster ePA
by Zacks Equity Research
athenahealth Inc. (ATHN) recently entered into a strategic partnership with CoverMyMeds.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
On Apr 10, we issued an updated research report Denver, CO-based DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure.
Masimo (MASI) Launches Root Platform with Kite Trademark
by Zacks Equity Research
Irvine, CA-based Masimo Corporation (MASI) announced full market release of the Root monitoring platform with a Kite trademark (a supplementary display system).
Zimmer Biomet (ZBH) Upgraded to Hold on Solid Prospects
by Zacks Equity Research
On Apr 7, leading musculoskeletal healthcare company Zimmer Biomet Holdings, Inc. (ZBH) was raised to a Zacks Rank #3 (Hold).